These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36507813)

  • 1. A practical update on the management of patients with COVID-19.
    Mehta M; Navarra A; Mogal R
    Clin Med (Lond); 2022 Sep; 22(5):468-474. PubMed ID: 36507813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir for the treatment of COVID-19.
    Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
    Kumar S; Çalışkan DM; Janowski J; Faist A; Conrad BCG; Lange J; Ludwig S; Brunotte L
    Front Immunol; 2021; 12():752227. PubMed ID: 34659259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
    Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
    BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
    Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
    Front Immunol; 2020; 11():569760. PubMed ID: 33362758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK.
    Goodwin AT; Thompson JS; Hall IP
    PLoS One; 2023; 18(3):e0281915. PubMed ID: 36920896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations.
    Passamonti F; Nicastri E; Di Rocco A; Guarini A; Ibatici A; Luminari S; Mikulska M; Visco C
    Hematol Oncol; 2023 Feb; 41(1):3-15. PubMed ID: 36251481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients.
    Bellino S
    Ann Med; 2022 Dec; 54(1):2856-2860. PubMed ID: 36259490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
    Narayanan D; Parimon T
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colchicine for the treatment of COVID-19.
    Mikolajewska A; Fischer AL; Piechotta V; Mueller A; Metzendorf MI; Becker M; Dorando E; Pacheco RL; Martimbianco ALC; Riera R; Skoetz N; Stegemann M
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD015045. PubMed ID: 34658014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing acute COVID-19 in immunocompromised pediatric patients.
    Mercolini F; Abram N; Cesaro S
    Expert Rev Clin Immunol; 2024 Apr; 20(4):349-357. PubMed ID: 38099388
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.